Fate Therapeutics (FATE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 12, 2026, at the company’s San Diego headquarters.
Stockholders of record as of April 15, 2026, are eligible to vote on key proposals.
Proxy materials, including the proxy statement and annual report, are available online and by request.
Voting matters and shareholder proposals
Election of three Class I directors: Robert S. Epstein, Karin Jooss, and Laura J. Hamill.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay).
Proposal to amend and restate the 2022 Stock Option and Incentive Plan to increase reserved shares.
Additional business may be transacted as appropriate at the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all four proposals presented.
Latest events from Fate Therapeutics
- FT819 advances off-the-shelf CAR T into lupus nephritis and broader autoimmune care.FATE
Jefferies Global Healthcare Conference - $100 million Leerink ATM adds financing flexibility but carries material dilution risk.FATE
Registration filing - RECLAIM-LN advanced as management’s grant-inclusive runway outlook extended to mid-2028.FATE
Q3 2026 - Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis.FATE
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss narrowed, cash runway into 2028, and pivotal CAR T-cell trials advanced.FATE
Q2 2026 - Early lupus trial data with flexible CAR T protocols expected by year-end, focusing on B-cell reset.FATE
Jefferies 2024 Global Healthcare Conference - FT819 and next-gen CAR T-cell therapies show strong clinical progress and financial stability.FATE
Corporate presentation - Net loss narrowed on lower expenses, with strong cash and key CAR T-cell advances, but risks remain.FATE
Q1 2026 - Shareholders will vote on director elections, auditor ratification, say-on-pay, and equity plan expansion.FATE
Proxy filing